Search research articles
Contact Us
Filters
Showing results (81-90 of 91) with videos related to
Page
of 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 5, 2021
Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study
Lauren Averett Byers, Dmitry Bentsion, Steven Gans, et al.
The Oncologist
|
March 11, 2022
Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials
J Connor Wells, Aven Sidhu, Keyue Ding, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 24, 2007
Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline
Katherine M W Pisters, William K Evans, Christopher G Azzoli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2009
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study
Glenwood D Goss, Andrew Arnold, Frances A Shepherd, et al.
British Journal of Cancer
|
February 19, 2016
Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients
Petra Martin, Carolyn J Shiau, Maria Pasic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 29, 2020
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
Nasser H Hanna, Bryan J Schneider, Sarah Temin, et al.
The Lancet. Oncology
|
December 3, 2014
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial
Peter M Ellis, Frances A Shepherd, Michael Millward, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2021
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
Nasser H Hanna, Andrew G Robinson, Sarah Temin, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 15, 2020
A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226
Rosalyn A Juergens, Desiree Hao, Peter M Ellis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2022
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline
Navneet Singh, Sarah Temin, Sherman Baker, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 91) with videos related to
Sort By:
Page
of 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 5, 2021
Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study
Lauren Averett Byers, Dmitry Bentsion, Steven Gans, et al.
The Oncologist
|
March 11, 2022
Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials
J Connor Wells, Aven Sidhu, Keyue Ding, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 24, 2007
Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline
Katherine M W Pisters, William K Evans, Christopher G Azzoli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2009
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study
Glenwood D Goss, Andrew Arnold, Frances A Shepherd, et al.
British Journal of Cancer
|
February 19, 2016
Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients
Petra Martin, Carolyn J Shiau, Maria Pasic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 29, 2020
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
Nasser H Hanna, Bryan J Schneider, Sarah Temin, et al.
The Lancet. Oncology
|
December 3, 2014
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial
Peter M Ellis, Frances A Shepherd, Michael Millward, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2021
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
Nasser H Hanna, Andrew G Robinson, Sarah Temin, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 15, 2020
A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226
Rosalyn A Juergens, Desiree Hao, Peter M Ellis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2022
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline
Navneet Singh, Sarah Temin, Sherman Baker, et al.
Page
of 10